Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | TMIGD3 | P0DMS9 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491807 | 0.82 | PDE5A (0.56) | PDE5ASMN1; SMN2ALDH1A1RAB9AMEN1 | |
| SCHEMBL3494101 | 0.79 | PDE5A (0.55) | PDE5ASMN1; SMN2ALDH1A1RAB9AMEN1 | |
| SCHEMBL4510358 | 0.77 | PDE5A (0.44) | PDE5ASMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL3491566 | 0.70 | ALDH1A1 (0.53) | SMN1; SMN2ALDH1A1RAB9AMEN1NPC1 | |
| SCHEMBL16175565 | 0.68 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1MEN1KMT2ABRD4 | |
| SCHEMBL4521870 | 0.67 | KMT2A (0.58) | ALDH1A1RAB9AMEN1NPC1KMT2A | |
| SCHEMBL3491341 | 0.67 | ALDH1A1 (0.52) | SMN1; SMN2ALDH1A1RAB9AMEN1NPC1 | |
| SCHEMBL38093 | 0.65 | PDE5A (0.55) | PDE5ASMN1; SMN2ALDH1A1RAB9ANPC1 | |
| Meglumine SCHEMBL21459168 | 0.64 | ALDH1A1 (0.42) | SMN1; SMN2ALDH1A1RAB9AMEN1NPC1 | |
| SCHEMBL4520288 | 0.64 | KMT2A (0.57) | ALDH1A1RAB9AMEN1NPC1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870656-B2 | Methods for treatment of heart failure | CARDURION PHARMACEUTICALS, LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190211028-A1 | METHODS FOR TREATMENT OF HEART FAILURE | CARDURION PHARMACEUTICALS LLC (US) | 2019-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10870656-B2 | Methods for treatment of heart failure | TNNT2, TNNI3, TNNC1 | PDE5A 251/4885SMN1; SMN2 1014/4885ALDH1A1 748/4885 |
| US-20190211028-A1 | METHODS FOR TREATMENT OF HEART FAILURE | TNNT2, TNNI3, TNNC1 | PDE5A 251/4885SMN1; SMN2 1014/4885ALDH1A1 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.